{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T20:51:51Z","timestamp":1771102311077,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.imlet.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T16:14:09Z","timestamp":1678205649000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Monocyte chemokine receptors as therapeutic targets in cardiovascular diseases"],"prefix":"10.1016","volume":"256-257","author":[{"given":"Danielle Borges","family":"Germano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffany Bernardo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Luis Lacerda","family":"Bachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y\u00e1ra","family":"Juliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil Ferreira","family":"Novo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f4natas","family":"Bussador do Amaral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Nunes","family":"Fran\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2023.03.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107799","article-title":"Role of inflammatory chemokines in hypertension","volume":"223","author":"Mikolajczyk","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"17","key":"10.1016\/j.imlet.2023.03.002_bib0002","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.3390\/jcm10173825","article-title":"Key chemokine pathways in atherosclerosis and their therapeutical potential","volume":"10","author":"M\u00e1rquez","year":"2021","journal-title":"J. Clin. Med."},{"issue":"Suppl","key":"10.1016\/j.imlet.2023.03.002_bib0003","first-page":"S82","article-title":"Chemokines and their receptors: roles in specific clinical conditions and measurement in the clinical laboratory","volume":"123","author":"Locati","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109647","article-title":"Role of chemokines, innate and adaptative immunity","volume":"73","author":"Zimmerman","year":"2020","journal-title":"Cell Signal."},{"key":"10.1016\/j.imlet.2023.03.002_bib0005","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/cvr\/cvv150","article-title":"Chemokines as effector and target molecules in vascular biology","volume":"107","author":"Sozzani","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.imlet.2023.03.002_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12265-020-10006-7","article-title":"Chemokines in myocardial infarction","volume":"14","author":"Chen","year":"2021","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.imlet.2023.03.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109363","article-title":"Latelet-secreted CCL3 and its receptor CCR5 promote invasive and migratory abilities of anaplastic thyroid carcinoma cells via MMP-1","volume":"63","author":"Wang","year":"2019","journal-title":"Cell Signal."},{"key":"10.1016\/j.imlet.2023.03.002_bib0008","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/bs.apcsb.2019.11.002","article-title":"Atherosclerosis: orchestrating cells and biomolecules involved in its activation and inhibition","volume":"120","author":"Munjal","year":"2020","journal-title":"Adv. Protein Chem. Struct. Biol."},{"issue":"24","key":"10.1016\/j.imlet.2023.03.002_bib0009","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1007\/s00018-019-03255-6","article-title":"Dual CCR5\/CCR2 targeting: opportunities for the cure of complex disorders","volume":"76","author":"Fantuzzi","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.imlet.2023.03.002_bib0010","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1182\/blood-2011-01-326827","article-title":"SuperSAGE evidence for CD14+ +CD16+ monocytes as a third monocyte subset","volume":"118","author":"Zawada","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2023.03.002_bib0011","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/CIRCULATIONAHA.107.743872","article-title":"Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-\/- mice: evidence for independent chemokine functions in atherogenesis","volume":"117","author":"Saederup","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.imlet.2023.03.002_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243788","article-title":"CX3CR1 is a prerequisite for the development of cardiac hypertrophy and left ventricular dysfunction in mice upon transverse aortic constriction","volume":"16","author":"Weisheit","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2023.03.002_bib0013","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1042\/CS20170009","article-title":"Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease","volume":"131","author":"Fran\u00e7a","year":"2017","journal-title":"Clin. Sci."},{"key":"10.1016\/j.imlet.2023.03.002_bib0014","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1111\/j.1582-4934.2012.01595.x","article-title":"Monocytic microparticles promote atherogenesis by modulating inflammatory cells in mice","volume":"16","author":"Hoyer","year":"2012","journal-title":"J. Cell. Mol. Med."},{"issue":"5","key":"10.1016\/j.imlet.2023.03.002_bib0015","doi-asserted-by":"crossref","first-page":"C797","DOI":"10.1152\/ajpcell.00330.2020","article-title":"Monocyte recruitment and fate specification after myocardial infarction","volume":"319","author":"Mentkowski","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0016","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jvssci.2022.04.001","article-title":"Modulation of interleukin-6 and its effect on late vein wall injury in a stasis mouse model of deep vein thrombosis","volume":"3","author":"Dowling","year":"2022","journal-title":"JVS Vasc. Sci."},{"key":"10.1016\/j.imlet.2023.03.002_bib0017","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/29788","article-title":"Decreased lesion formation in CCR2-\/- mice reveals a role for chemokines in the initiation of atherosclerosis","volume":"394","author":"Boring","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2023.03.002_bib0018","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/ATVBAHA.112.300773","article-title":"Monocyte chemoattractant protein 1\u2013mediated migration of mesenchymal stem cells is a source of intimal hyperplasia","volume":"33","author":"Grudzinska","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0019","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.7211","article-title":"Characterization of monocyte chemoattractant proteins and CC chemokine receptor 2 expression during atherogenesis in apolipoprotein E-null mice","volume":"18","author":"Zhang","year":"2011","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.imlet.2023.03.002_bib0020","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/01.RES.0000149518.86865.3e","article-title":"Crucial role of the CCL2\/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets","volume":"95","author":"Schober","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.imlet.2023.03.002_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10557-008-6157-0","article-title":"A CCR2\/CCR5 antagonist attenuates an increase in angiotensin II-induced CD11b+ monocytes from atherogenic ApoE-\/- mice","volume":"23","author":"Major","year":"2009","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.imlet.2023.03.002_bib0022","article-title":"Intermitent fasting inhibits high-fat diet-induced atherosclerosis by ameliorating hypercholesterolemia and reducing monocyte chemoattraction","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6642927","article-title":"The entry and egress of monocytes in atherosclerosis: a biochemical and biomechanical driven process","volume":"2021","author":"Kang","year":"2021","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.imlet.2023.03.002_bib0024","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1161\/01.CIR.103.16.2096","article-title":"New anti\u2013monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E\u2013knockout mice","volume":"103","author":"Ni","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.imlet.2023.03.002_bib0025","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nbt.1989","article-title":"Therapeutic siRNA silencing in inflammatory monocytes in mice","volume":"29","author":"Leuschner","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0026","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.112.000116","article-title":"Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice","volume":"127","author":"Majmudar","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.imlet.2023.03.002_bib0027","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.2147\/IJN.S178650","article-title":"Effect of CCR2 inhibitor-loaded lipid micelles on inflammatory cell migration and cardiac function after myocardial infarction","volume":"13","author":"Wang","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.imlet.2023.03.002_bib0028","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7150\/ntno.37391","article-title":"Nano-antagonist alleviates inflammation and allows for MRI of atherosclerosis","volume":"3","author":"Mog","year":"2019","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.imlet.2023.03.002_bib0029","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.atherosclerosis.2009.08.017","article-title":"CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE\u2212\/\u2212 mice","volume":"208","author":"Aiello","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.imlet.2023.03.002_bib0030","doi-asserted-by":"crossref","first-page":"F1288","DOI":"10.1152\/ajprenal.00316.2013","article-title":"CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice","volume":"305","author":"Sullivan","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0031","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/ATVBAHA.109.198812","article-title":"Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2\/apolipoprotein E-\/- mouse: magnetic resonance maging assessment","volume":"30","author":"Olzinski","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0032","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neuint.2019.02.010","article-title":"Propagermanium, a CCR2 inhibitor, attenuates cerebral ischemia\/reperfusion injury through inhibiting inflammatory response induced by microglia","volume":"125","author":"He","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.imlet.2023.03.002_bib0033","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1248\/bpb.b12-00528","article-title":"A novel C\u2013C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models","volume":"35","author":"Okamoto","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.imlet.2023.03.002_bib0034","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1161\/01.ATV.0000253886.44609.ae","article-title":"Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice","volume":"27","author":"Braunersreuther","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0035","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/j.atherosclerosis.2007.03.026","article-title":"CC chemokine receptor 5 influences late-stage atherosclerosis","volume":"195","author":"Quinones","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.imlet.2023.03.002_bib0036","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0021-9150(02)00382-9","article-title":"CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice","volume":"167","author":"Kuziel","year":"2003","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.imlet.2023.03.002_bib0037","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.3390\/ijms21186567","article-title":"CCL4 inhibition in atherosclerosis: effect on plaque stability, endotelial cell adhesiveness, and macrophage activation","volume":"21","author":"Chang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.imlet.2023.03.002_bib0038","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/ATVBAHA.111.240358","article-title":"Accelerated atherosclerosis in Apoe-\/- mice heterozygous for the insulin receptor and the insulin receptor substrate-1","volume":"32","author":"Galkina","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"19","key":"10.1016\/j.imlet.2023.03.002_bib0039","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152511","article-title":"IL-35 promotes CD4+Foxp3+ Tregs and inhibits atherosclerosis via maintaning CCR5-amplified Treg-suppressive mechanisms","volume":"6","author":"Shao","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.imlet.2023.03.002_bib0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yjmcc.2021.03.010","article-title":"Role of myeloid-derived chemokine CCL5\/RANTES at an early stage of atherosclerosis","volume":"156","author":"Jongstra-Bilen","year":"2021","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0041","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/01.RES.0000109793.17591.4E","article-title":"Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice","volume":"94","author":"Veillard","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.imlet.2023.03.002_bib0042","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/eurheartj\/ehr127","article-title":"CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice","volume":"33","author":"Montecucco","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.imlet.2023.03.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.000874","article-title":"CCR5 inhibition prevents cardiac dysfunction in the SIV\/macaque model of HIV","volume":"3","author":"Kelly","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.imlet.2023.03.002_bib0044","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1161\/CIRCULATIONAHA.113.001278","article-title":"Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice","volume":"127","author":"Cipriani","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.imlet.2023.03.002_bib0045","doi-asserted-by":"crossref","first-page":"16789","DOI":"10.1073\/pnas.0507718102","article-title":"Molecular evidence for arterial repair in atherosclerosis","volume":"102","author":"Karra","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.imlet.2023.03.002_bib0046","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11010-013-1604-z","article-title":"Role of CC-chemokine receptor 5 on myocardial ischemia-reperfusion injury in rats","volume":"378","author":"Shen","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.imlet.2023.03.002_bib0047","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1161\/ATVBAHA.108.165423","article-title":"A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice","volume":"28","author":"Braunersreuther","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.imlet.2023.03.002_bib0048","doi-asserted-by":"crossref","first-page":"ofz112","DOI":"10.1093\/ofid\/ofz112","article-title":"Maraviroc intensification modulates atherosclerotic progression in HIV-supressed patients at a high cardiovascular risk. A randomized, crossover pilot study","volume":"6","author":"Francisci","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.imlet.2023.03.002_bib0049","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1084\/jem.20081385","article-title":"CX3CR1+ CD115+ CD135+ common macrophage\/DC precursors and the role of CX3CR1 in their response to inflammation","volume":"206","author":"Auffray","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2023.03.002_bib0050","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cvr\/cvv111","article-title":"Chemokine receptors CXCR2 and CX3CR1 differentially regulate functional responses of bone-marrow endothelial progenitors during atherosclerotic plaque regression","volume":"106","author":"Herlea-Pana","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.imlet.2023.03.002_bib0051","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/01.CIR.0000057548.68243.42","article-title":"Decreased atherosclerotic lesion formation in CX3CR1\/apolipoprotein E double knockout mice","volume":"107","author":"Combadi\u00e8re","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.imlet.2023.03.002_bib0052","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1172\/JCI15555","article-title":"Decreased atherosclerosis in CX3CR1-\/- mice reveals a role for fractalkine in atherogenesis","volume":"111","author":"Lesnik","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.imlet.2023.03.002_bib0053","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.biomaterials.2015.07.059","article-title":"A novel CX3CR1 antagonist eluting stent reduces stenosis by targeting inflammation","volume":"69","author":"Ali","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.imlet.2023.03.002_bib0054","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/ATVBAHA.112.300930","article-title":"Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice","volume":"33","author":"Poupel","year":"2013","journal-title":"Aterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0055","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1161\/CIRCULATIONAHA.107.745091","article-title":"Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice","volume":"117","author":"Combadi\u00e8re","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.imlet.2023.03.002_bib0056","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/01.ATV.19.9.2085","article-title":"Expression of CCR2 by endothelial cells. Implications for MCP-1 mediated wound injury repair and in vivo inflammatory activation of endothelium","volume":"19","author":"Weber","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0057","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.amjcard.2010.11.005","article-title":"Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region","volume":"107","author":"Gilbert","year":"2011","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.imlet.2023.03.002_bib0058","doi-asserted-by":"crossref","first-page":"e00159","DOI":"10.1002\/edm2.159","article-title":"Propagermanium administration for patients with type 2 diabetes and nephropathy: a randomized pilot trial","volume":"3","author":"Hara","year":"2020","journal-title":"Endocrinol. Diabetes Metab."},{"key":"10.1016\/j.imlet.2023.03.002_bib0059","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/joim.12145","article-title":"Increased proatherogenic monocyte-platelet cross-talk in monocyte subpopulations of patients with stable coronary artery disease","volume":"275","author":"Czepluch","year":"2014","journal-title":"J. Int. Med."},{"key":"10.1016\/j.imlet.2023.03.002_bib0060","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/ATVBAHA.110.221150","article-title":"The spatial and developmental relationships in the macrophage family","volume":"31","author":"Swirski","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0061","doi-asserted-by":"crossref","first-page":"e46312","DOI":"10.1371\/journal.pone.0046312","article-title":"Arteriolar and venular remodeling are differentially regulated by bone-marrow-derived cell-specific CX3CR1 and CCR2 expression","volume":"7","author":"Meisner","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2023.03.002_bib0062","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/ATVBAHA.114.304650","article-title":"Nonclassical patrolling monocyte function in the vasculature","volume":"35","author":"Thomas","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0063","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.atherosclerosis.2015.07.031","article-title":"The impact of CCR5-\u039432 deletion on C-reactive protein levels and cardiovascular disease: results from the Danish Blood Donor Study","volume":"242","author":"Dinh","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.imlet.2023.03.002_bib0064","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1161\/STROKEAHA.107.504381","article-title":"Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population","volume":"39","author":"Afzal","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.imlet.2023.03.002_bib0065","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1365-2796.2005.01491.x","article-title":"CC chemokine receptor 5 (CCR5) deletion polymorphism does not protect Czech males against early myocardial infarction","volume":"257","author":"Petrkova","year":"2005","journal-title":"J. Int. Med."},{"key":"10.1016\/j.imlet.2023.03.002_bib0066","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20022156","article-title":"Fractalkine preferentially mediates arrest and migration of CD16+ monocytes","volume":"197","author":"Ancuta","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2023.03.002_bib0067","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2008-07-170787","article-title":"CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival","volume":"113","author":"Landsman","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.imlet.2023.03.002_bib0068","doi-asserted-by":"crossref","first-page":"e10680","DOI":"10.1002\/jbm4.10680","article-title":"The fractalkine-CX3CR1 axis regulates non-inflammatory osteoclastogenesis by enhancing precursor cell survival","volume":"6","author":"Kuboi","year":"2022","journal-title":"JBMR Plus"},{"key":"10.1016\/j.imlet.2023.03.002_bib0069","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cyto.2014.05.022","article-title":"Fractalkine levels are elevated early after PCI-treated ST-elevation myocardial infarction; no influence of autologous bone marrow derived stem cell injection","volume":"69","author":"Njerve","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.imlet.2023.03.002_bib0070","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.thromres.2015.03.020","article-title":"Chemokine CX3CL1 and its receptor CX3CR1 are associated with human atherosclerotic lesion volnerability","volume":"135","author":"Zhang","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.imlet.2023.03.002_bib0071","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI28180","article-title":"Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines","volume":"117","author":"Cheng","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.imlet.2023.03.002_bib0072","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1161\/ATVBAHA.115.306359","article-title":"Chemokines","volume":"35","author":"van der Vorst","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0073","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1189\/jlb.1009671","article-title":"Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases","volume":"88","author":"Zhao","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0074","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/emmm.201201717","article-title":"Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes","volume":"5","author":"Soehnlein","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.imlet.2023.03.002_bib0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-030-73234-9_11","article-title":"The role of chemokines in cardiovascular diseases and the therapeutic effect of curcumin on CXCL8 and CCL2 as pathological chemokines in atherosclerosis","volume":"1328","author":"Hedayati-Moghadam","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"issue":"10","key":"10.1016\/j.imlet.2023.03.002_bib0076","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1002\/jcp.30375","article-title":"The molecular structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in skeletal biology and diseases","volume":"236","author":"Zhu","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"43","key":"10.1016\/j.imlet.2023.03.002_bib0077","doi-asserted-by":"crossref","first-page":"73693","DOI":"10.18632\/oncotarget.17793","article-title":"Mesenchymal stem cells in inflammatory microenvironment potently promote metastatic growth of cholangiocarcinoma via activating Akt-NK-k\u03b2 signaling by paracrine CCL5","volume":"8","author":"Zhong","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.imlet.2023.03.002_bib0078","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2174\/1389203720666190305165722","article-title":"Crosstalk between the CX3CL1\/CX3CR1 axis and inflammatory signaling pathways in tissue injury","volume":"20","author":"Zhuang","year":"2019","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.imlet.2023.03.002_bib0079","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1161\/ATVBAHA.112.300134","article-title":"Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis","volume":"32","author":"Tall","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.imlet.2023.03.002_bib0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/13543776.2013.771168","article-title":"Progress in the discovery of CC chemokine receptor 2 antagonists, 2009-2012","volume":"23","author":"Carter","year":"2013","journal-title":"Expert Opin. Ther. Patol."},{"key":"10.1016\/j.imlet.2023.03.002_bib0081","article-title":"Role of the CCL2-CCR2 axis in cardiovascular disease: pathogenesis and clinical implications","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.imlet.2023.03.002_bib0082","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1021\/jm3012273","article-title":"Substituted 7-amino-5-thio-thiazolo [4,5-dipypyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1)","volume":"56","author":"Karlstr\u00f6m","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.imlet.2023.03.002_bib0083","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1709322","article-title":"VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis","volume":"12","author":"Low","year":"2020","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.imlet.2023.03.002_bib0084","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1042\/BJ20150520","article-title":"AZD8797 is an allosteric non-competitive modulator of the human CX3CR1 receptor","volume":"473","author":"Cederblad","year":"2016","journal-title":"Biochem. J."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247823000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247823000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:42:08Z","timestamp":1759045328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247823000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":84,"alternative-id":["S0165247823000378"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2023.03.002","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monocyte chemokine receptors as therapeutic targets in cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}